A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens.

MLA

Chevalier, Rachel, et al. “A Fresh Look at Proton Pump Inhibitor (PPI)-Associated Adverse Events through a CYP2C19 Pharmacogenetic Lens.” Expert Opinion on Drug Metabolism & Toxicology, vol. 19, no. 2, Feb. 2023, pp. 53–56. EBSCOhost, https://doi.org/10.1080/17425255.2023.2190883.

APA

Chevalier, R., Attard, T., Van Driest, S. L., & Shakhnovich, V. (2023). A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens. Expert Opinion on Drug Metabolism & Toxicology, 19(2), 53–56. https://doi.org/10.1080/17425255.2023.2190883

Chicago

Chevalier, Rachel, Thomas Attard, Sara L Van Driest, and Valentina Shakhnovich. 2023. “A Fresh Look at Proton Pump Inhibitor (PPI)-Associated Adverse Events through a CYP2C19 Pharmacogenetic Lens.” Expert Opinion on Drug Metabolism & Toxicology 19 (2): 53–56. doi:10.1080/17425255.2023.2190883.